drugset
drugset / Trial / NCT05113745

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

NCT05113745 ↗

Phase 3 Completed 68 enrolled Axsome Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).

Timeline

Start
2021-10-20
Primary completion
2024-11-15
Completion
2024-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject AXS-12 Unknown — —

Indications

narcolepsy-cataplexy syndrome